Arch Therapeutics (ARTH)
(Delayed Data from OTC)
$0.52 USD
0.00 (0.00%)
Updated Aug 28, 2024 02:42 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Arch Therapeutics, Inc falls in the month of September.
All items in Millions except Per Share data.
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 0 | 1 | 2 | 1 | 2 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1 | 1 | 1 | 1 | 0 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 2 | 3 | 4 | 2 | 3 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 2 | 3 | 4 | 2 | 3 |
Liabilities & Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Notes Payable | 6 | 1 | 0 | 0 | 0 |
Accounts Payable | 2 | 1 | 0 | 0 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 1 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 1 | 0 | 0 |
Total Current Liabilities | 9 | 3 | 2 | 1 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 3 | 2 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 1 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 1 | 1 | 2 | 3 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 9 | 7 | 5 | 4 | 4 |
Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 55 | 51 | 49 | 42 | 38 |
Retained Earnings | -62 | -55 | -50 | -44 | -39 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -8 | -4 | -1 | -2 | -1 |
Total Liabilities & Shareholder's Equity | 2 | 3 | 4 | 2 | 3 |
Total Common Equity | -8 | -4 | -1 | -2 | -1 |
Shares Outstanding | 3.00 | 1.20 | 1.10 | 0.90 | 0.90 |
Book Value Per Share | -2.50 | -3.49 | -0.94 | -1.67 | -0.90 |
Fiscal Year End for Arch Therapeutics, Inc falls in the month of September.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 0 | 0 | 0 | 0 | 0 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1 | 1 | 1 | 1 | 1 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 1 | 2 | 2 | 2 | 2 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 1 | 2 | 2 | 2 | 2 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 9 | 7 | 6 | 6 | 4 |
Accounts Payable | 3 | 3 | 3 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 1 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 1 | 1 | 1 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 1 | 0 | 1 |
Total Current Liabilities | 14 | 12 | 11 | 9 | 10 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 14 | 12 | 11 | 9 | 10 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 60 | 55 | 55 | 55 | 52 |
Retained Earnings | -73 | -66 | -65 | -62 | -60 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -13 | -11 | -10 | -8 | -8 |
Total Liabilities & Shareholder's Equity | 1 | 2 | 2 | 2 | 2 |
Total Common Equity | -13 | -11 | -10 | -8 | -8 |
Shares Outstanding | 4.70 | 4.70 | 4.70 | 3.00 | 1.20 |
Book Value Per Share | -2.67 | -2.31 | -2.04 | -2.50 | -6.68 |